63 related articles for article (PubMed ID: 10601597)
1. Preoperative evaluation by whole-body 18F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer.
Mukai M; Sadahiro S; Yasuda S; Ishida H; Tokunaga N; Tajima T; Makuuchi H
Oncol Rep; 2000; 7(1):85-7. PubMed ID: 10601597
[TBL] [Abstract][Full Text] [Related]
2. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.
Abdel-Nabi H; Doerr RJ; Lamonica DM; Cronin VR; Galantowicz PJ; Carbone GM; Spaulding MB
Radiology; 1998 Mar; 206(3):755-60. PubMed ID: 9494497
[TBL] [Abstract][Full Text] [Related]
3. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F
Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
[TBL] [Abstract][Full Text] [Related]
4. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
5. [18F-fluorodeoxyglucose positron emission tomography in colorectal cancer: value in primary staging and follow-up].
Jörg L; Heinisch M; Rechberger E; Kurz F; Klug R; Aufschnaiter M; Hammer J; Langsteger W
Acta Med Austriaca; 2002; 29(5):176-9. PubMed ID: 12506769
[TBL] [Abstract][Full Text] [Related]
6. Implication of ¹⁸F-Fluorodeoxyglucose Uptake of Affected Axillary Lymph Nodes in Cases with Breast Cancer.
Fujii T; Yajima R; Tatsuki H; Oosone K; Kuwano H
Anticancer Res; 2016 Jan; 36(1):393-7. PubMed ID: 26722071
[TBL] [Abstract][Full Text] [Related]
7. Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice.
Ruhlmann J; Schomburg A; Bender H; Oehr P; Robertz-Vaupel GM; Vaupel H; Wolter H; Kozak B; Biersack HJ
Dis Colon Rectum; 1997 Oct; 40(10):1195-204. PubMed ID: 9336115
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI.
Schöder H; Carlson DL; Kraus DH; Stambuk HE; Gönen M; Erdi YE; Yeung HW; Huvos AG; Shah JP; Larson SM; Wong RJ
J Nucl Med; 2006 May; 47(5):755-62. PubMed ID: 16644744
[TBL] [Abstract][Full Text] [Related]
9. 18 F-fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: a prospective study.
Hitier-Berthault M; Ansquer C; Branchereau J; Renaudin K; Bodere F; Bouchot O; Rigaud J
Int J Urol; 2013 Aug; 20(8):788-96. PubMed ID: 23279605
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography imaging of colorectal cancer.
Akhurst T; Larson SM
Semin Oncol; 1999 Oct; 26(5):577-83. PubMed ID: 10528907
[TBL] [Abstract][Full Text] [Related]
11. [Positron emission tomography. Introduction of a new procedure in diagnosis of urologic tumors and initial clinical results].
Bachor R; Kocher F; Gropengiesser F; Reske SN; Hautmann RE
Urologe A; 1995 Mar; 34(2):138-42. PubMed ID: 7754585
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography of breast cancer in detecting axillary lymph node metastasis: comparison with ultrasonography and contrast-enhanced CT.
Monzawa S; Adachi S; Suzuki K; Hirokaga K; Takao S; Sakuma T; Hanioka K
Ann Nucl Med; 2009 Dec; 23(10):855-61. PubMed ID: 19876704
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography in the evaluation of the negative neck in patients with oral cavity cancer.
Myers LL; Wax MK
J Otolaryngol; 1998 Dec; 27(6):342-7. PubMed ID: 9857320
[TBL] [Abstract][Full Text] [Related]
14. A new imaging technique for colorectal cancer: positron emission tomography.
Flamen P; Van Cutsem E; Mortelmans L
Semin Oncol; 2000 Oct; 27(5 Suppl 10):22-9. PubMed ID: 11049029
[No Abstract] [Full Text] [Related]
15. The role of positron emission tomography in the management of colorectal cancer.
Tutt AN; Plunkett TA; Barrington SF; Leslie MD
Colorectal Dis; 2004 Jan; 6(1):2-9. PubMed ID: 14692944
[TBL] [Abstract][Full Text] [Related]
16. More than meets the eye: 2-[
Huang W; Son MH; Ha LN; Kang L; Cai W
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1725-1728. PubMed ID: 38424238
[No Abstract] [Full Text] [Related]
17. Incidental focal hypermetabolic colorectal lesions identified by positron emission tomography: prevalence of malignancy.
Shie P
Abdom Imaging; 2011 Apr; 36(2):165-9. PubMed ID: 20458476
[TBL] [Abstract][Full Text] [Related]
18. PET/CT in Colorectal Cancer.
Schiepers C
J Nucl Med; 2003 Nov; 44(11):1804-5. PubMed ID: 14602863
[No Abstract] [Full Text] [Related]
19. Comparison of positron emission tomography and computed tomography in detection of recurrent and metastatic colorectal cancer.
Cohen AM
Ann Surg Oncol; 1997 Dec; 4(8):610. PubMed ID: 9416405
[No Abstract] [Full Text] [Related]
20. [A patient with colorectal cancer and tuberculosis: false positive in PET and its clinical implication].
Pérez López ME; García Gómez J; Fírvida Pérez JL; García Mata J
Med Clin (Barc); 2005 Mar; 124(9):357. PubMed ID: 15760608
[No Abstract] [Full Text] [Related]
[Next] [New Search]
